9886 — Dingdang Health Technology Balance Sheet
0.000.00%
- HK$1.39bn
- HK$200.42m
- CNY4.67bn
- 37
- 55
- 95
- 72
Annual balance sheet for Dingdang Health Technology, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 582 | 1,553 | 1,348 | 1,329 | 1,218 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 122 | 200 | 292 | 289 | 301 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,093 | 2,268 | 2,528 | 2,372 | 2,202 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 198 | 214 | 217 | 194 | 206 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,786 | 2,946 | 3,297 | 3,065 | 2,633 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 602 | 739 | 969 | 913 | 832 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3,145 | 5,558 | 1,112 | 1,027 | 972 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | -1,358 | -2,612 | 2,186 | 2,037 | 1,660 |
| Total Liabilities & Shareholders' Equity | 1,786 | 2,946 | 3,297 | 3,065 | 2,633 |
| Total Common Shares Outstanding |